Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CABALA trial of panitumumab plus cisplatin and pemetrexed in EGFR FISH-positive advanced non-squamous NSCLC
2010-021092-89Phase 2Terminated
- Sponsor
- Southern Italy Cooperative Oncology Group
- Start
- Sep 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab, cisplatin and pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Southern Italy Cooperative Oncology Group. Primary endpoint: 6-month progression-free survival rate. Started Sep 2010; status: terminated.
02
Drugs
panitumumabcisplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-021092-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021092-89.